We investigated the influence of mild hypothermic cardiopulmonary bypass (CPB) on the dose requirements of cisatracurium or rocuronium used as a continuous infusion. We studied eight patients given cisatracurium and nine given rocuronium. They were ASA class III and IV and scheduled for elective coronary artery bypass grafting. Neuromuscular transmission was monitored electromyographically. After recovery of T1/T0 to 10%, a cisatracurium infusion or a rocuronium infusion was started at a rate of 1.5 or 10 µg kg -1 min -1 , respectively, and adjusted to maintain T1/T0 at 15%. Infusion rate and duration were recorded before, during and after CPB in each patient and the mean infusion rates were calculated. One-way ANOVA showed a statistically significant difference between the cisatracurium infusion rates before, during and after CPB: A T1/T0 of 15% could be achieved with a mean infusion rate of 1.1, 0.75 and 0.98 µg kg -1 min -1 before, during and after CPB, respectively. There was no significant difference between the rocuronium infusion rates before, during and after CPB. The mean rocuronium infusion rate required to maintain T1/T0 at 15% throughout the procedure was 4.1 µg kg -1 min -1 . Cisatracurium infusion rates should be halved during CPB. Even after CPB, requirements are reduced. The same tendency occurs with rocuronium, but the changes in infusion rate were not statistically significant. Neuromuscular blocking drugs are commonly used during data for the newer neuromuscular blocking drugs are scarce, coronary artery bypass grafting (CABG). Their advantages cisatracurium and rocuronium infusion rates during and are that they aid mechanical ventilation, decrease anaesthetic after CPB are adjusted empirically. requirements, prevent patient movement and decrease A more rational dosage regimen may reduce waste and, oxygen consumption. Cisatracurium and rocuronium gener-consequently, the cost of using these expensive new drugs. ally lack cardiovascular side-effects during high-dose opioid Moreover, a more predictable recovery may be important anaesthesia 1 2 and thus have advantages for use during in fast tracking and minimally invasive cardiac procedures, CABG procedures. These advantages may not, however, be as it may allow early extubation. Avoiding an excessively observed in different clinical conditions. 3 During CABG prolonged neuromuscular block may also decrease the and, more particularly, during cardiopulmonary bypass incidence of awareness during the first hours on the intensive (CPB), cisatracurium and rocuronium requirements have care unit (ICU). not been studied in detail.
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Drug elimination may be reduced by relative hypo-Methods perfusion of the liver and kidney or by hypothermia during After Institutional Review Board approval and written CPB. 4 This is true for atracurium 5 and for rocuronium. 6 informed consent, we studied eight patients given cisatracurMoreover, as the clearance of cisatracurium, one of the ium followed by nine given rocuronium during CABG with stereoisomers of atracurium, is highly dependent on mild hypothermic CPB (33°C). All patients were ASA class Hofmann degradation, 7 temperature and pH changes associ-III and IV. Exclusion criteria were: left ventricular ejection ated with CPB are likely to affect its pharmacokinetics more than those of other neuromuscular blocking drugs. As fraction Ͻ50%; evidence of renal, hepatic, metabolic or Infusion rate and infusion duration were recorded before, (left radial artery) and central venous pressure (right jugular during and after CPB for each patient. The mean infusion vein). Temperature was monitored at the following sites: rates in both groups were derived before, during and after oesophagus, rectum, skin of the forehead and the area of bypass. Statistical analysis included one-way analysis of skin on the right arm where neuromuscular transmission variance (ANOVA). Significance was set at a level of monitoring electrodes had been applied.
PϽ0.05. A one-sample t-test was performed to assess if The bypass circuit was of standard construction. Blood the derived mean (actual T1/T0%) was significantly different temperature was measured at the venous site of the bypass from the theoretical mean (T1/T0ϭ15%). Results are precircuit and kept constant at 33°C during hypothermia. sented as mean (SD). Rewarming to 37°C was started as soon as the surgeon had completed the last distal anastomosis. Alpha-stat pH Results management was used.
Neuromuscular transmission was monitored on the right Anaesthesia was uneventful in all patients. No patient moved and no diaphragmatic contractions were observed. arm by the EMG response of the adductor pollicis muscle to TOF stimulation of the ulnar nerve, using surface There was no need for any escape bolus dose of neuromuscular blocking drug. Patients did not sweat and their eyes did electrodes (M-NMT module; Datex-Ohmeda, Helsinki, Finland). The right arm was wrapped in a protective towel. not water. They did not recall the operation. One patient in the cisatracurium group suffered from opioid-induced rigidThe TOF response to a supramaximal stimulus was obtained before the initial bolus of neuromuscular blocking drug. ity during induction. Although assisted ventilation was initially difficult, oxygenation was well maintained and The stimulus current range during supramaximal stimulation was 10-70 mA. The TOF was measured at 1 min intervals, induction was otherwise uneventful. Table 1 shows the physical characteristics of the patients using a square wave, constant current stimulus pulse with a width of 200 µs.
in the cisatracurium and rocuronium groups. The mean (SD) time between starting the initial infusion of cisatracurium After recovery of T1/T0 to 10%, patients were given either cisatracurium or rocuronium, at an infusion rate of at a rate of 1.5 µg kg -1 min -1 and the first adjustment to a lower dose was 34.5 (19.1) min. In the cisatracurium group, 1.5 and 10 µg kg -1 min -1 , respectively. These dosages were based on data obtained during major non-cardiac surgery. 8 9 mean (SD) T1/T0 during the procedure was 14.6 (9.9)%.
This actual mean was not significantly different from the The infusion rate was adjusted to maintain T1/T0 at 15%. The concentration of the solutions used for infusion was preset value (T1/T0ϭ15%) (Pϭ0.7). Table 2 shows the one-way ANOVA of cisatracurium infusion rates during 0.2 and 1 mg ml -1 for cisatracurium and rocuronium, respectively, so that even small changes in infusion rate led CABG. The means differ significantly (Pϭ0.01), with the highest rate before and the lowest during CPB. to significant changes of volume delivered and, thus, to a quick alteration in effect. The infusion was discontinued
The mean (SD) time between starting the rocuronium infusion at the initial infusion rate (10 µg kg -1 min -1 ) and just before the completion of surgery. Bolus doses of cisatracurium 0.03 mg kg -1 or rocuronium 0.15 mg kg -1 the first adjustment to a lower dose was 20.2 (13.3) min.
In the rocuronium group, the mean (SD) T1/T0 during the were given if gross movement occurred. Spontaneous recovery from neuromuscular blockade was allowed on the procedure was 14.2 (7.1) %; this was not significantly different from the preset value (T1/T0ϭ15%) (Pϭ0.2). ICU. The results of monitoring neuromuscular transmission and all other vital parameters were displayed on a Datex Table 2 shows the one-way ANOVA of rocuronium infusion rates during CABG. There was no statistically significant AS/3 monitor and stored in a spreadsheet on a PC (Compaq). difference between these means (Pϭ0.5). The mean (SD) It has been shown that, for various neuromuscular infusion rate of rocuronium required to keep T1/T0 at 15% blocking drugs, the duration of action is prolonged by throughout surgery was 4.1 (1.6) µg kg -1 min -1 .
CPB. 10-14 19 The half-life of cisatracurium is presumably prolonged during hypothermic CPB, as its breakdown is Discussion even more dependent on temperature and pH than that of atracurium, for which a reduced dose requirement has been During hypothermic CPB, complex changes in drug pharobserved during CPB. 5 The remainder of the drug, about macokinetics occur, prolonging the duration of action of 15%, is cleared by the kidneys. 15 The pharmacokinetics of many non-depolarizing neuromuscular blocking drugs. 4 The rocuronium resemble those of vecuronium, except that serum concentration of neuromuscular blocking drugs may the former has a smaller volume of distribution. 16 The decrease when bypass is started, as a result of haemodilutermination of the effect of rocuronium is similar to vecurontion, 10 11 or it may increase secondary to decreased clearance ium and mainly dependent on redistribution, by hepatic and altered drug distribution. 12 13 uptake, followed by biliary elimination. A smaller proporThe impairment of the metabolic function of the kidney, tion, Ͻ20%, is excreted renally. 20 Smeulers and colleagues 6 as a result of hypoperfusion during CPB is expected to found that hypothermic CPB prolonged the duration of decrease renal elimination. 14 Moreover, decreased hepatic action of maintenance doses of rocuronium. blood flow, decreased concentration of binding proteins and
In a preliminary study, 21 we concluded that a cisatracurdecreased intrinsic activity of the liver are assumed to ium infusion, administered at half the initial rate (0.75 µg diminish hepatic clearance during bypass. 14 These phenkg -1 min -1 ) during hypothermic CPB, resulted in clinically omena may result in a steady increase in the serum concentration of neuromuscular blocking drugs during hypo-acceptable conditions. Discontinuation of the cisatracurium thermic CPB. 14 Hypothermia itself can alter the pharmaco-infusion at the start of CPB, on the contrary, led to an kinetics of drugs during CPB: it influences the enzymatic unacceptably high incidence of movement, suggesting that processes involved in drug metabolism in the liver and it is preferable to use a continuous infusion of neuromuscular kidneys. 4 blocking agent during CABG and CPB. In the current study, Finally, since neuromuscular blocking drugs may redis-we confirmed our previous findings that a cisatracurium tribute significantly to the lungs, they can accumulate there infusion rate of 0.75 µg kg -1 min -1 was appropriate during before bypass begins. These drugs can thus become trapped CPB. Moreover, we found that a T1/T0 of 15% could be in the lungs during CPB, as circulation to the lungs during achieved before CPB with a dose of Ͻ1.5 µg kg -1 min -1 . that period is restricted to the bronchial vessels. When Even after the bypass, cisatracurium infusion rates were pulmonary artery blood flow is restored during weaning lower than those before bypass, probably because of a from CPB, the serum concentration of these drugs may further fall in body temperature, a tendency described in suddenly increase. 4 14 previous reports for other neuromuscular blocking drugs. 5 Rosen and Rosen 4 concluded that pharmacokinetics dur-Less rocuronium was required during and, to a lesser extent, ing CPB depend mainly on the composition of the after CPB compared with before CPB, but the differences oxygenator, the physical properties of the drug, the use of in infusion rates were not statistically significant. In the pulsatile or non-pulsatile flow and hypothermia. Drugs rocuronium group, we also observed a temperature afterwith a smaller distribution volume are more affected. The drop in the period after the bypass. oxygenator binds lipophilic drugs more avidly than those
We have searched for a practical and adequate infusion that are hydrophilic. Neuromuscular blocking drugs gener-regimen for the two latest commercially available neuromusally have a rather small distribution volume: cisatracurium cular blocking drugs, cisatracurium and rocuronium, during has a slightly greater volume of distribution than atracur-cardiac surgery with mild hypothermic CPB. For cisatracurium, 15 while rocuronium has a smaller one than vecu-ium, we found that a significant reduction to half of the ronium. 16 initial infusion rate during CPB was appropriate in clinical In clinical practice, serum concentrations of neuromuscu-practice. As with atracurium, the cause is probably related lar blocking drugs are not available. The degree of muscle to the temperature-dependent inactivation of cisatracurium. relaxation can only be assessed by monitoring neuromuscu-For rocuronium, a lower infusion rate was used in our study lar transmission. However, neuromuscular monitoring dur-than in previous reports. 9 Further reduction during CPB ing hypothermia is complicated by the fact that cooling was not necessary. The degree of cooling during CPB may affects nerve conduction, neuromuscular transmission and explain the discrepancy between our results and those of muscular activity. 17 The evoked response obtained in a other investigators: while Smeulers and colleagues 6 cooled peripheral muscle during CPB may be influenced by peri-patients to 25-28°C, we used only mild hypothermia (33°C). pheral and core temperature gradients and alterations in skeletal muscle blood flow. Nevertheless, in the presence of hypothermia, pH disturbances and the side-effects of Acknowledgement simple clinical judgment. 18 
